Health Care & Life Sciences » Biotechnology | Acorda Therapeutics Inc.

Acorda Therapeutics Inc.

Acorda Therapeutics Inc.
Stock Exchange NASDAQ Stock Market
EPS
$0.12
Market Cap
$354.24 M
Shares Outstanding
48.13 M
Public Float
46.73 M

Profile

Address
420 Saw Mill River Road
Ardsley New York 10502
United States
Employees -
Website http://www.acorda.com
Updated 07/08/2019
Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. Its two main products are Ampyra and Zanaflex Capsules. The Ampyra is an oral drug, which treats to improve walking in patients with multiple sclerosis and Zanaflex Capsules, which is a short acting drug for the management of spasticity, a symptom of many central nervous system disorders, including multiple sclerosis and spinal cord injury.

Financials

View All

Ronald Cohen
President, Chief Executive Officer & Director
Catherine D. Strader
Independent Director